A four-compound fat metabolism blend — AOD-9604, MOTS-C, Tesamorelin, and Ipamorelin — studied for lipolysis, GH axis support, body composition, and mitochondrial optimization. Physician-reviewed. Prescription required.
AOD 9604 is a small peptide derived from the C-terminal fragment of human growth hormone (hGH). Unlike full-length GH, AOD 9604 is designed to stimulate fat metabolism without affecting blood sugar or growth of other tissues. Its primary action is on lipid metabolism pathways, rather than traditional GH–IGF-1 signaling. MOTS-c is a mitochondria-derived peptide (MDP) that acts as a metabolic regulator encoded by mitochondrial DNA, primarily affecting cellular energy metabolism, insulin sensitivity, and mitochondrial function.
Together, these compounds target fat metabolism from complementary angles — AOD-9604 through direct lipolysis, and MOTS-c through mitochondrial and insulin-sensitizing mechanisms. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| Lipolysis activation | Breakdown of stored fat |
| Inhibition of lipogenesis | Reduces fat storage |
| Selective GH fragment | Minimal IGF-1 effects |
| Tissue repair (minor) | Slight cartilage/ECM support |
| Mitochondrial fat oxidation | Increased energy utilization from fat |
| Mechanism | Biological Effect |
|---|---|
| AMPK activation | Increased glucose uptake & fat oxidation |
| Enhanced insulin sensitivity | Improved glucose homeostasis |
| Mitochondrial biogenesis | Better energy production & endurance |
| Anti-inflammatory signaling | Reduced metabolic inflammation |
| Fat metabolism modulation | Reduced adiposity |
| Mitonuclear signaling | Adaptive metabolic gene expression |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with AOD-9604 / MOTS-c protocol candidates in clinical practice:
Fat Loss Protocol
Individuals with physician-confirmed adiposity seeking targeted metabolic support.
Insulin Sensitivity
Individuals with metabolic syndrome components where MOTS-c's AMPK activation may be clinically relevant.
Endurance & Energy
Athletes or executives seeking mitochondrial optimization and metabolic efficiency support.
Combination Protocol
Patients combining AOD-9604 with Tesamorelin or Ipamorelin in a physician-reviewed metabolic stack.
Determine your candidacy
A physician will review your intake and make eligibility determination within 24–48 hours.
All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.
Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
AOD: 300 mcg–1.2 mg/day; MOTS-c: 2–10 mg/week
Administration
Subcutaneous injection
Duration
12–24 weeks (physician-determined)
Frequency
Daily to 3x weekly (physician-determined)
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.